Wedbush Equities Analysts Boost Earnings Estimates for ITOS

Key Points

• Wedbush has raised its Q3 2025 EPS estimates for iTeos Therapeutics to ($1.70) per share, up from a previous estimate of ($2.07), maintaining an "Outperform" rating and a target price of $10.50.
• Analysts' sentiments about iTeos Therapeutics have mixed ratings, with Wells Fargo lowering their price target from $12.00 to $11.00 and multiple firms downgrading their ratings recently.
• The company reported a Q2 earnings miss, posting ($1.51) EPS, which was below the consensus estimate of ($1.12).

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Investment analysts at Wedbush raised their Q3 2025 EPS estimates for iTeos Therapeutics in a report issued on Wednesday, August 6th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($1.70) per share for the quarter, up from their previous forecast of ($2.07). Wedbush has a "Outperform" rating and a $10.50 price target on the stock. The consensus estimate for iTeos Therapeutics' current full-year earnings is ($3.49) per share. Wedbush also issued estimates for iTeos Therapeutics' Q4 2025 earnings at ($0.21) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.31) EPS.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.51) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.39).

ITOS has been the topic of a number of other research reports. Raymond James Financial set a $12.00 target price on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Leerink Partnrs lowered iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Leerink Partners reaffirmed a "market perform" rating and issued a $9.00 price target (down previously from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Wells Fargo & Company lowered their price target on iTeos Therapeutics from $12.00 to $11.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th. Finally, Piper Sandler lowered iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 21st. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $15.50.

iTeos Therapeutics Stock Down 0.0%

Shares of ITOS stock traded down $0.01 during mid-day trading on Monday, reaching $10.12. 187,576 shares of the company's stock traded hands, compared to its average volume of 932,780. iTeos Therapeutics has a 12 month low of $4.80 and a 12 month high of $18.13. The company has a market cap of $447.18 million, a P/E ratio of -2.17 and a beta of 1.49. The company's 50-day moving average price is $10.12 and its 200-day moving average price is $8.21.

Insider Activity

In other news, CEO Michel Detheux sold 43,883 shares of the company's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $10.02, for a total transaction of $439,707.66. Following the completion of the sale, the chief executive officer owned 153,903 shares of the company's stock, valued at $1,542,108.06. This represents a 22.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David Hallal sold 38,228 shares of the company's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $10.24, for a total transaction of $391,454.72. The disclosure for this sale can be found here. Insiders have sold a total of 277,185 shares of company stock valued at $2,805,412 in the last ninety days. Insiders own 14.20% of the company's stock.

Institutional Investors Weigh In On iTeos Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio bought a new position in shares of iTeos Therapeutics during the 1st quarter valued at approximately $31,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of iTeos Therapeutics during the 4th quarter valued at approximately $42,000. CWM LLC boosted its position in shares of iTeos Therapeutics by 428.7% during the 1st quarter. CWM LLC now owns 8,554 shares of the company's stock valued at $51,000 after acquiring an additional 6,936 shares during the last quarter. Paloma Partners Management Co bought a new position in shares of iTeos Therapeutics during the 1st quarter valued at approximately $65,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of iTeos Therapeutics during the 1st quarter valued at approximately $67,000. 97.16% of the stock is owned by hedge funds and other institutional investors.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.